SorCS3 Antibody (339615) [Alexa Fluor® 594]

• Reactivity: Mu
• Applications: WB, IHC
• Clone: 339615
• Clonality: Monoclonal
• Host: Rat
• Conjugate: Alexa Fluor 594

SorCS3 Antibody (339615) [Alexa Fluor® 594] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse SorCS3
  Glu34-Ser1122
  Accession # Q8VI51
• Specificity: Detects human and mouse SorCS3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human SorCS1 is observed.
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Rat
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for SorCS3 Antibody (339615) [Alexa Fluor® 594]

• 6330404A12Rik
• KIAA1059SORCS
• SorCS3
• sortilin-related VPS10 domain containing receptor 3
• VPS10 domain receptor protein SORCS 3 (SORCS3)
• VPS10 domain-containing receptor SorCS3

Background

SorCS3 is a type I transmembrane receptor of the mammalian Vps10p (vacuolar protein-sorting 10 protein) family of receptors that includes sortilin, SorLA, and three SorCS proteins (1, 2). It is synthesized as a 1219 amino acid (aa) preproform with a 33 aa signal sequence and a 100 aa propeptide. After proteolytic release of the propeptide at a furin-type consensus sequence, the mature SorCS3 is a 1086 aa, 100 - 110 kDa protein with a 992 aa extracellular/lumenal domain (ECD), a 21 aa transmembrane domain and a 73 aa cytoplasmic domain. Mouse SorCS3 ECD shares 98%, 92%, 91% and 89% aa identity with rat, human, bovine and canine SorCS3 ECD, respectively. It also shares 65% and 44% aa identity with mouse SorCS1 and SorCS2 ECD, respectively. The ECD contains an imperfect leucine-rich repeat (LRR) and a Vps10p domain that binds both pro- and mature NGF (2, 3). The metalloproteinase TACE/ADAM17 is able to cleave SorCS3 near the membrane either constitutively, or at an increased rate when induced by phorbol esters (4). The shed ECD is able to bind PDGF-BB and the NGF propeptide (4). Unlike sortilin, the SorCS3 propeptide has no known function; it does not block NGF binding or propeptide cleavage (3, 5). SorCS3 is predominantly expressed on the plasma membrane (3). It can be slowly internalized but, despite the presence of a sorting domain, there is no evidence for SorCS3-mediated intracellular trafficking activity (3). It is expressed in the embryonic and adult central nervous system in areas distinct from that of SorCS1 and SorCS2 (1). Neuronal activity upregulates SorCS3 expression in the hippocampus (1).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.